Publication

Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease

van Aalst, R., Russo, E. M., Neupane, N., Mahmud, S. M., Mor, V., Wilschut, J., Chit, A., Postma, M. & Young-Xu, Y., 26-Jul-2019, In : Vaccine. 37, 32, p. 4499-4503 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van Aalst, R., Russo, E. M., Neupane, N., Mahmud, S. M., Mor, V., Wilschut, J., ... Young-Xu, Y. (2019). Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease. Vaccine, 37(32), 4499-4503. https://doi.org/10.1016/j.vaccine.2019.06.066

Author

van Aalst, Robertus ; Russo, Ellyn M. ; Neupane, Nabin ; Mahmud, Salaheddin M. ; Mor, Vincent ; Wilschut, Jan ; Chit, Ayman ; Postma, Maarten ; Young-Xu, Yinong. / Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population : Estimating the impact on hospitalization cost for cardio-respiratory disease. In: Vaccine. 2019 ; Vol. 37, No. 32. pp. 4499-4503.

Harvard

van Aalst, R, Russo, EM, Neupane, N, Mahmud, SM, Mor, V, Wilschut, J, Chit, A, Postma, M & Young-Xu, Y 2019, 'Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease', Vaccine, vol. 37, no. 32, pp. 4499-4503. https://doi.org/10.1016/j.vaccine.2019.06.066

Standard

Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population : Estimating the impact on hospitalization cost for cardio-respiratory disease. / van Aalst, Robertus; Russo, Ellyn M.; Neupane, Nabin; Mahmud, Salaheddin M.; Mor, Vincent; Wilschut, Jan; Chit, Ayman; Postma, Maarten; Young-Xu, Yinong.

In: Vaccine, Vol. 37, No. 32, 26.07.2019, p. 4499-4503.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van Aalst R, Russo EM, Neupane N, Mahmud SM, Mor V, Wilschut J et al. Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease. Vaccine. 2019 Jul 26;37(32):4499-4503. https://doi.org/10.1016/j.vaccine.2019.06.066


BibTeX

@article{cdbce47fd0494a11896accf128d087cf,
title = "Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: Estimating the impact on hospitalization cost for cardio-respiratory disease",
abstract = "Objective: To compare the economic impact of high-dose trivalent (HD) versus standard-dose trivalent (SD) influenza vaccination on direct medical costs for cardio-respiratory hospitalizations in adults aged 65 years or older enrolled in the United States (US) Veteran's Health Administration (VHA). Methods: Leveraging a relative vaccine effectiveness study of HD versus SD over five respiratory seasons (2010/11 through 2014/15), we collected cost data for healthcare provided to the same study population both at VHA and through Medicare services. Our economic assessment compared the costs of vaccination and hospital care for patients experiencing acute cardio-vascular or respiratory illness. Results: We analyzed 3.5 million SD and 158,636 HD person-seasons. The average cost of HD and SD vaccination was $23.48 (95{\%} CI: $21.29 - $25.85) and $12.21 (95{\%} CI: $11.49 - $13.00) per recipient, respectively, while the hospitalization rates for cardio-respiratory disease in HD and SD recipients were 0.114 (95{\%} CI: 0.108–0.121) and 0.132 (95{\%} CI: 0.132–0.133) per person-season, respectively. Attributing the average cost per hospitalization of $11,796 (95{\%} CI: $11,685 - $11,907) to the difference in hospitalization rates, we estimated savings attributable to HD to be $202 (95{\%} CI: $115 – $280) per vaccinated recipient. Conclusions: For the five-season period of 2010/11 through 2014/15, HD influenza vaccination was associated with net cost savings due to fewer hospitalizations, and therefore lower direct medical costs, for cardio-respiratory disease as compared to SD influenza vaccination in the senior US VHA population.",
keywords = "Economic assessment, High-dose vaccine, Influenza",
author = "{van Aalst}, Robertus and Russo, {Ellyn M.} and Nabin Neupane and Mahmud, {Salaheddin M.} and Vincent Mor and Jan Wilschut and Ayman Chit and Maarten Postma and Yinong Young-Xu",
year = "2019",
month = "7",
day = "26",
doi = "10.1016/j.vaccine.2019.06.066",
language = "English",
volume = "37",
pages = "4499--4503",
journal = "Vaccine",
issn = "0264-410X",
publisher = "ELSEVIER SCI LTD",
number = "32",

}

RIS

TY - JOUR

T1 - Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population

T2 - Estimating the impact on hospitalization cost for cardio-respiratory disease

AU - van Aalst, Robertus

AU - Russo, Ellyn M.

AU - Neupane, Nabin

AU - Mahmud, Salaheddin M.

AU - Mor, Vincent

AU - Wilschut, Jan

AU - Chit, Ayman

AU - Postma, Maarten

AU - Young-Xu, Yinong

PY - 2019/7/26

Y1 - 2019/7/26

N2 - Objective: To compare the economic impact of high-dose trivalent (HD) versus standard-dose trivalent (SD) influenza vaccination on direct medical costs for cardio-respiratory hospitalizations in adults aged 65 years or older enrolled in the United States (US) Veteran's Health Administration (VHA). Methods: Leveraging a relative vaccine effectiveness study of HD versus SD over five respiratory seasons (2010/11 through 2014/15), we collected cost data for healthcare provided to the same study population both at VHA and through Medicare services. Our economic assessment compared the costs of vaccination and hospital care for patients experiencing acute cardio-vascular or respiratory illness. Results: We analyzed 3.5 million SD and 158,636 HD person-seasons. The average cost of HD and SD vaccination was $23.48 (95% CI: $21.29 - $25.85) and $12.21 (95% CI: $11.49 - $13.00) per recipient, respectively, while the hospitalization rates for cardio-respiratory disease in HD and SD recipients were 0.114 (95% CI: 0.108–0.121) and 0.132 (95% CI: 0.132–0.133) per person-season, respectively. Attributing the average cost per hospitalization of $11,796 (95% CI: $11,685 - $11,907) to the difference in hospitalization rates, we estimated savings attributable to HD to be $202 (95% CI: $115 – $280) per vaccinated recipient. Conclusions: For the five-season period of 2010/11 through 2014/15, HD influenza vaccination was associated with net cost savings due to fewer hospitalizations, and therefore lower direct medical costs, for cardio-respiratory disease as compared to SD influenza vaccination in the senior US VHA population.

AB - Objective: To compare the economic impact of high-dose trivalent (HD) versus standard-dose trivalent (SD) influenza vaccination on direct medical costs for cardio-respiratory hospitalizations in adults aged 65 years or older enrolled in the United States (US) Veteran's Health Administration (VHA). Methods: Leveraging a relative vaccine effectiveness study of HD versus SD over five respiratory seasons (2010/11 through 2014/15), we collected cost data for healthcare provided to the same study population both at VHA and through Medicare services. Our economic assessment compared the costs of vaccination and hospital care for patients experiencing acute cardio-vascular or respiratory illness. Results: We analyzed 3.5 million SD and 158,636 HD person-seasons. The average cost of HD and SD vaccination was $23.48 (95% CI: $21.29 - $25.85) and $12.21 (95% CI: $11.49 - $13.00) per recipient, respectively, while the hospitalization rates for cardio-respiratory disease in HD and SD recipients were 0.114 (95% CI: 0.108–0.121) and 0.132 (95% CI: 0.132–0.133) per person-season, respectively. Attributing the average cost per hospitalization of $11,796 (95% CI: $11,685 - $11,907) to the difference in hospitalization rates, we estimated savings attributable to HD to be $202 (95% CI: $115 – $280) per vaccinated recipient. Conclusions: For the five-season period of 2010/11 through 2014/15, HD influenza vaccination was associated with net cost savings due to fewer hospitalizations, and therefore lower direct medical costs, for cardio-respiratory disease as compared to SD influenza vaccination in the senior US VHA population.

KW - Economic assessment

KW - High-dose vaccine

KW - Influenza

U2 - 10.1016/j.vaccine.2019.06.066

DO - 10.1016/j.vaccine.2019.06.066

M3 - Article

VL - 37

SP - 4499

EP - 4503

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 32

ER -

ID: 90394131